Erkinantti, S., Hautakoski, A., Sund, R., Arffman, M., Urpilainen, E., Puistola, U., Läärä, E., Jukkola, A., & Karihtala, P. (2022). The Association of Metformin, Other Antidiabetic Medications and Statins on the Prognosis of Rectal Cancer in Patients with Type 2 Diabetes: A Retrospective Cohort Study. Biomolecules, 12(9), 1301. https://doi.org/10.3390/biom12091301
The association of metformin, other antidiabetic medications and statins on the prognosis of rectal cancer in patients with type 2 diabetes : a retrospective cohort study
|Author:||Erkinantti, Sami1; Hautakoski, Ari1,2; Sund, Reijo3;|
1Medical Research Center Oulu, Oulu University Hospital and University of Oulu, P.O. Box 8000, 90014 Oulu, Finland
2Department of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, P.O. Box 23, 90029 Oulu, Finland
3Institute of Clinical Medicine, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland
4Department of Public Health and Welfare Finnish Institute for Health and Welfare, P.O. Box 30, 00271 Helsinki, Finland
5Research Unit of Mathematical Sciences, University of Oulu, P.O. Box 3000, 90014 Oulu, Finland
6Department of Oncology and Radiotherapy, Tampere University Hospital, Cancer Center Tampere, Faculty of Medicine and Health Technology, Tampere University, P.O. Box 2000, 33521 Tampere, Finland
7Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center and University of Helsinki, P.O. Box 180, 00029 Helsinki, Finland
|Online Access:||PDF Full Text (PDF, 0.8 MB)|
|Persistent link:|| http://urn.fi/urn:nbn:fi-fe2022101361819
Multidisciplinary Digital Publishing Institute,
|Publish Date:|| 2022-10-13
Metformin and statin use have been associated with an improved prognosis for colorectal cancer in persons with type 2 diabetes (T2D). Data regarding rectal cancer (RC) have been inconclusive; therefore, we investigated the issue with high-quality data and a robust study design. We identified 1271 eligible patients with T2D and incident RC between 1998 and 2011 from the Diabetes in Finland (FinDM) database. Cox models were fitted for cause-specific mortality rates to obtain adjusted estimates of the hazard ratios (HR) with 95% confidence intervals (CI) in relation to use of antidiabetic medication (ADM) and statins before the RC diagnosis and for post-diagnostic use in a time-dependent exposure manner. No sufficient evidence was found for either pre- or post-diagnostic metformin use and RC mortality (HR 0.96, 95% CI 0.67–1.38, and 0.70, 95% CI 0.45–1.10, respectively) when compared to other oral ADMs. Both pre- and post-diagnostic statin use appeared to be inversely associated with mortality from RC (HR 0.77 95% CI 0.63–0.94, and 0.57, 95% CI 0.42–0.78, respectively). Our study was inconclusive as to the association of metformin use with the prognosis of RC, but statin use was found to predict reduced mortality, both from RC and from other causes of death in persons with T2D.
|Type of Publication:||
A1 Journal article – refereed
|Field of Science:||
This study was supported by the Society of Jane and Aatos Erkko [T59127], Finnish Government Research Funds allocated to the University Hospital of Oulu [K77729], and personal funding from the University of Oulu Scholarship Foundation, The Finnish Oncology Society, and the Orion Research Foundation.
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).